The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis

Abstract

Listen

Translate article

To the Editor: In plaque psoriasis clinical trials, ≥75% reduction in the psoriasis area and severity index (PASI75) has traditionally been the benchmark for treatment efficacy.1 With the advent of newer biologics, PASI90 or PASI100 are becoming the new standard.1 Studies have shown that higher skin clearance is associated with better short-term patient-reported outcomes (PROs), such as symptom control and health-related quality of life (HRQL).2 This study quantified the long-term impact on patient quality of life of achieving and maintaining complete-clearance (PASI100) and near-clearance (PASI90-99) compared to moderate-clearance (PASI75-89).